NeuroSense Updates Business Presentation with New Data on Slides 4 & 29
Ticker: NRSNW · Form: 6-K · Filed: Jan 9, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-update, presentation, investor-relations
TL;DR
**NeuroSense just dropped an updated presentation, check slides 4 & 29 for new info!**
AI Summary
NeuroSense Therapeutics Ltd. filed a 6-K on January 9, 2024, to provide an updated business presentation, specifically noting new information on slides 4 and 29. This update, signed by CEO Alon Ben-Noon, is important for investors because it offers the latest insights into the company's business, potentially influencing their perception of its future prospects and stock value, especially regarding its pharmaceutical preparations.
Why It Matters
This filing matters because it provides investors with the most current information about NeuroSense Therapeutics Ltd.'s business, which could impact investment decisions and stock valuation.
Risk Assessment
Risk Level: medium — While a presentation update isn't inherently high-risk, the content of the new slides could contain information that significantly alters the company's risk profile, making it a medium risk until reviewed.
Analyst Insight
A smart investor would immediately review the updated presentation, specifically slides 4 and 29, to understand the new information and assess its potential impact on NeuroSense Therapeutics Ltd.'s valuation and future prospects before making any investment decisions.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — the registrant filing the 6-K
- Alon Ben-Noon (person) — Chief Executive Officer who signed the filing
- January 9, 2024 (date) — date of the filing and presentation update
Forward-Looking Statements
- NeuroSense Therapeutics Ltd. will likely see increased investor interest following the review of the updated presentation. (NeuroSense Therapeutics Ltd.) — medium confidence, target: Q1 2024
FAQ
What is the purpose of NeuroSense Therapeutics Ltd.'s 6-K filing on January 9, 2024?
The purpose of the 6-K filing is to make available an updated presentation about NeuroSense Therapeutics Ltd.'s business, which includes new information on slides 4 and 29.
Who signed the 6-K report on behalf of NeuroSense Therapeutics Ltd.?
The 6-K report was signed by Alon Ben-Noon, the Chief Executive Officer of NeuroSense Therapeutics Ltd., on January 9, 2024.
Which specific slides in the updated presentation contain new information?
The updated presentation contains new information on slides 4 and 29, as stated in the filing.
What is the Commission File Number for NeuroSense Therapeutics Ltd.?
NeuroSense Therapeutics Ltd.'s Commission File Number is 001-41084.
What is the business address of NeuroSense Therapeutics Ltd. as listed in the filing?
The business address of NeuroSense Therapeutics Ltd. is 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Filing Stats: 257 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-01-09 08:48:26
Filing Documents
- ea191333-6k_neurosense.htm (6-K) — 10KB
- ea191333ex99-1_neurosense.htm (EX-99.1) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 97KB
- ex99-1_002.jpg (GRAPHIC) — 965KB
- ex99-1_003.jpg (GRAPHIC) — 73KB
- ex99-1_004.jpg (GRAPHIC) — 77KB
- ex99-1_005.jpg (GRAPHIC) — 115KB
- ex99-1_006.jpg (GRAPHIC) — 108KB
- ex99-1_007.jpg (GRAPHIC) — 115KB
- ex99-1_008.jpg (GRAPHIC) — 147KB
- ex99-1_009.jpg (GRAPHIC) — 86KB
- ex99-1_010.jpg (GRAPHIC) — 108KB
- ex99-1_011.jpg (GRAPHIC) — 97KB
- ex99-1_012.jpg (GRAPHIC) — 69KB
- ex99-1_013.jpg (GRAPHIC) — 102KB
- ex99-1_014.jpg (GRAPHIC) — 95KB
- ex99-1_015.jpg (GRAPHIC) — 71KB
- ex99-1_016.jpg (GRAPHIC) — 111KB
- ex99-1_017.jpg (GRAPHIC) — 86KB
- ex99-1_018.jpg (GRAPHIC) — 97KB
- ex99-1_019.jpg (GRAPHIC) — 79KB
- ex99-1_020.jpg (GRAPHIC) — 98KB
- ex99-1_021.jpg (GRAPHIC) — 73KB
- ex99-1_022.jpg (GRAPHIC) — 116KB
- ex99-1_023.jpg (GRAPHIC) — 123KB
- ex99-1_024.jpg (GRAPHIC) — 130KB
- ex99-1_025.jpg (GRAPHIC) — 116KB
- ex99-1_026.jpg (GRAPHIC) — 105KB
- ex99-1_027.jpg (GRAPHIC) — 711KB
- ex99-1_028.jpg (GRAPHIC) — 104KB
- ex99-1_029.jpg (GRAPHIC) — 108KB
- ex99-1_030.jpg (GRAPHIC) — 90KB
- ex99-1_031.jpg (GRAPHIC) — 84KB
- ex99-1_032.jpg (GRAPHIC) — 87KB
- ex99-1_033.jpg (GRAPHIC) — 140KB
- 0001213900-24-002052.txt ( ) — 6636KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: January 9, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2